Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Residential Real Estate Crash Index -- Ignore unavailable to you. Want to Upgrade?

To: grusum who wrote (212569)	7/26/2009 4:59:44 PM
From: Skeeter Bug	Read Replies (2) \| Respond to of 306849

>>from drugs to treatments, everything good from the medical industry has been driven by profit in the free market.<< but not the importance of diet, which will reduce the use of those drugs and reduce profits. so less than 1% of people have any clue what a good diet is and the government even promotes a bad diet by subsidizing foods that are patently bad for you (but increase profits!).

To: grusum who wrote (212569)	7/26/2009 8:16:18 PM
From: NOW	Read Replies (1) \| Respond to of 306849

sorry, i was asking about health systems: the finest examples i know of Are ALL non-profit. so i ask you, can you point me to successful for-profit examples for improving the heath of a population? and your examples are all over-rated. the evidence is abundant that most of those breakthrough drugs and treatments were indeed developed at least in part by public monies

To: grusum who wrote (212569)	7/27/2009 3:49:10 AM
From: NOW	Read Replies (1) \| Respond to of 306849

"The few drugs that are truly innovative have usually been based on taxpayer-supported research done in nonprofit academic medical centers or at the National Institutes of Health. In fact, many drugs now sold by drug companies were licensed to them by academic medical centers or small biotechnology companies." The pharmaceutical industry estimates that each new drug costs them $800 million to develop and bring to market, but Angell and Relman estimate the cost to them is actually closer to $100 million. Examples are imatinib (Gleevec), zidovudine (AZT) and erythropoietin (Epogen). An unpublished internal NIH study in February 2000 of the 5 top-selling drugs in 1995 (Zantac, Zovirax, Capoten, Vasotec, and Prozac) found that 16 of the 17 key scientific papers leading to the discovery and development came from outside industry.